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Abstract ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J) mice were inoculated with 
Mycobacterium bovis BCG harbouring plasmids carrying the gene for isocitrate lyase. The presence 
of ~29 times more copies of this gene resulted in a higher bacterial yield in the spleens and lungs of 
the infected mice. The spleen was 3-4 times heavier, and in the spleen the bacteria survived over 10 
days longer than did the bacteria with the control plasmid. Propionate was less toxic for bacteria 
carrying icl plasmids in vitro. This recombinant BCG can be a possible vaccine candidate.  
 
Keywords BCG  immunization  isocitrate lyase  M. tuberculosis 
 3 
 Introduction 
 
More than one-third of the world’s population is infected with tuberculosis (TB) bacilli. 
Mycobacterium tuberculosis is a very successful pathogen. There were an estimated 9.4 million 
new cases of TB in 2009 and an estimated 1.7 million deaths (including 380 000 people with HIV), 
making this disease one of the world's most significant infectious killers. Millennium Development 
Goal 6 is that the incidence of TB should be falling by 2015 [1].  
 Although Mycobacterium bovis BCG is the only approved vaccine used for the prevention 
of TB in humans, the protective efficacy of the BCG vaccine varies widely in different parts of the 
world, reaching a maximum of 78% [2]. Most current efforts to improve the level of protective 
immunity provided by BCG include the development of recombinant BCG vaccines expressing 
different antigens [3]. 
 The survival of M. tuberculosis in infected macrophages requires the activity of isocitrate 
lyase (Icl), a key enzyme in the glyoxylate cycle. The glyoxylate shunt permits the effective 
utilization of two-carbon compounds, such as acetate (from the β-oxidation of fatty acids), to satisfy 
carbon requirements [4]. The glyoxylate cycle is required for the virulence of other bacteria and 
fungi [5, 6]. In mycobacteria, Icl has a dual role in the metabolism of fatty acids. It participates in 
the methylcitrate cycle too [7]. β-oxidation of odd-chain or branched-chain fatty acids results in the 
production of propionyl-CoA which is toxic for bacteria and fungi. [8,9]. Propionyl-CoA is 
metabolised in the methylcitrate cycle. The other way to use up proponyl-CoA is the methylmalonyl 
pathway. It requires a vitamin-B12-derived cofactor [10]. 
 A key to the intracellular survival of M. tuberculosis is its ability to prevent the fusion of 
phagosomes containing the internalized bacterium with the lysosomal system of the host cell. The 
addition of certain exogenous fatty acids modulates phagosome maturation, resulting in the killing 
of pathogenic bacteria, whereas other fatty acids stimulate pathogen growth [11]. Thus the role of 
lipids is multifaceted.  
 We used ApoB100-only LDLR-/-  mice to determine the survival of M. bovis BCG carrying 
plasmids coding for Icl. This double-knock-out (KO) mouse strain produces only apolipoprotein-B-
100 and is deficient in low-density lipoprotein (LDL) receptors. This mouse model has a lipid 
profile similar to that in most humans with atherosclerosis. Extended BCG survival is observed if 
the bacteria carry plasmids with the gene coding for Icl. We assume that this increased survival can 
result in more effective protection. 
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Materials and methods 
 
Bacterial strains and growth conditions 
M. bovis BCG was grown in Middlebrook 7H9 broth or 7H10 agar (Difco Laboratories, Detroit, 
MI, USA) enriched with 10% Middlebrook OADC (oleic acid/albumin/dextrose/catalase) (Difco) 
and 0.05% Tween 80 (Sigma–Aldrich Chemie GmbH, Steinheim, Germany) with the appropriate 
antibiotic. Escherichia coli DH5α was used for plasmid preparation. 
 
Plasmid construction 
 
We constructed pMV262(icl), which carries icl after the mycobacterial icl promoter (GenBank 
accession no. CAE55284.1) in pMV262 [12]. I1 5’-ACT ATC TAG ATC CGC AGG ACG TCG 
A-3 and I2 5′-GTA AGC TTC AGA CTA GTG GAA CTG G-3′ primers were used to synthetize icl 
with M. tuberculosis H37Rv chromosomal DNA as template. Primers were planned by using the 
sequence of H37Rv [13]. The PCR amplification conditions were as recommended by the 
manufacturer, with a GeneAmp II (Applied Biosystems, Foster City, CA, USA) thermocycler with 
Advantage GC cDNA polymerase (BD Biosciences Clontech, Mountain View, CA, USA). The 
amplified DNA was cut with XbaI and HindIII and inserted into pMV262 opened with the same 
enzymes.  
 
Gene copy number determination 
 
The High Pure PCR Template Preparation Kit (Roche Diagnostic GmbH, Mannheim, Germany; 
Cat. No.: 1796828) was used for DNA extraction. Each DNA sample was analysed in triplicate. The 
reaction volume was 15 l, containing 3 l of DNA, 1 mol/l of each of the primers (2l), 7.5 l of 
reaction buffer (IQ 2X Supermix, Bio-Rad Laboratories, Hercules, CA, USA) 0.6 μl of 
EVAGreen (20x EVAGreen™ Biotium Inc., Hayward, CA, USA) and 1.9 μl of distilled water. We 
used the forward primer 5′-AGC GCA TAT GTC TGT CGT CGG-3′ and reverse primer 5′-GTA 
AGC TTC AGA CTA GTG GAA CTG G-3′ for icl. The reference gene (GenBank accession no. 
O53899) primer set was 5’ TGG CAT ATG AAC CGG CAA CCT ATC 3’ and 5’ GAG GAT CCT 
CAT TCA TAG GAC GTG 3’. The primer sets have very similar efficiencies. A BIO-RAD CFX 
96 instrument (Bio-Rad, Hercules, CA, USA) was used for quantitation. The PCR conditions were 
initial denaturation at 95 °C for 10 min, followed by 35 cycles of denaturation (94 °C for 20 s), 
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annealing (55 °C for 30 s) and extension (68 °C for 45 s). The emitted fluorescence was measured 
after the extension step.  
Quantitation was performed by online monitoring for identification of the exact time point at which 
the logarithmic linear phase could be distinguished from the background (crossing point). The gene 
copy number was calculated by the ΔCt method with Bio-Rad CFX Manager 1.1 Gene Expression 
software. 
 
Electroporation of M. bovis BCG  
Competent M. bovis BCG prepared in 10% glycerol was transformed with pMV262 or 
pMV262(icl) by electroporation with a Gene Pulsar (Bio-Rad, München, Germany) set at 2.5 kV 
and 25 µF, and with the pulse controller resistance set at 1,000  [14, 15]. Transformed BCG was 
selected on Middlebrook 7H10 agar plates supplemented with 30 µg/ml kanamycin.  
Mouse experiments 
We used ApoB100-only LDLR-/- (B6;129S-ApoBtm2SgyLdlrtm1Her/J; 16 females per group and their 
weight ranged from 25-30 g) with the genetic background of a mixture of C57BL/6 and a particular 
129 strain from Jackson Laboratories (Bar Harbor, Maine, USA). These mice express full-length 
ApoB-100 in their LDL particles and have 3-fold higher plasma levels of ApoB100 than those in 
LDLR−/− mice. The mice were maintained under standard husbandry conditions and were supplied 
with food and water ad libitum. Intraperitoneal infection of the KO mice was started at 12-14 weeks 
of age and consisted of 100 µl of PBS containing 106 colony-forming units (CFU) of either 
BCGpMV262 or BCGpMV262(icl). Four mice from each group were sacrificed on days 10, 14, 21 
and 35 post-infection. The mice were euthanized and their spleens and lungs were excised. 
All experiments complied with the University of Szeged Guidelines for the Use of 
Laboratory Animals. 
 
Culturing of BCG from the lungs and the spleen 
The dissected spleens were homogenized by pressing them through nylon mesh into PBS (1 ml) 
containing 0.05% Tween 20. The lungs were removed and homogenized mechanically in 1 ml of 
PBS containing 0.05% Tween 20. 100 µl of tissue suspension was used. Ten fold dilutions of these 
suspensions were plated on Middlebrook 7H10 agar for cultivation of the bacteria.  CFUs were 
determined after 21 days of incubation at 37°C. 
 
 
 
 6 
Western blot  
 
Cell lysates of E. coli over-expressing Icl and purified control (chlamydial LcrH) [16] protein were 
heated to 95°C for 5 min in sample buffer and separated by SDS-10% PAGE. The separated 
proteins were blotted onto a polyvinylidene difluoride membrane (SERVA Heidelberg, Germany). 
The membranes were blocked with PBS containing 5% skim milk and 0.05% Tween 20 overnight 
at 4°C. Membranes were probed with BCGpMV262(icl) immunized and control (BCG pMV262) 
mouse homogenized lungs (1:10 dilution in 5% skim milk and 0.05% Tween 20 containing PBS). 
After washings, the filter was incubated with HRP-conjugated anti-mouse IgG for 2 hours, and the 
colour was developed using diaminobenzidine tetrahydrochloride (DAB, Sigma) with hydrogen 
peroxide in 10 mM Tris pH 7.5 according to the manufacturer’s instructions.  
 
  
Statistical analysis 
 
Statistical analysis of the data was carried out with GraphPad Prism 5 software, using the Student t 
test. Differences were considered significant at P<0.005. 
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Results  
 
The copy number of the pMV262(icl) in the BCG strain used for infection was 29. Figure 1 shows 
the spleen weights of mice infected with BCG carrying Icl plasmids and the control. Twenty one 
days after infection, the spleens from mice that were infected with bacteria that carried the 
additional icl genes were three to four times larger than those of the controls (Fig. 2).  
 Bacteria with one copy of icl (the chromosomal gene) appeared in the spleen earlier and 
their clearance was faster than that from the lungs (Fig. 3). In the spleen, very few bacteria were 
found 21 days after infection and they had disappeared by the end of the experiment (35 days), 
whereas some bacteria were still detected in the lungs at this time. Bacteria containing the plasmid 
with the icl gene survived much longer and their yield was 8-250 times higher (Fig. 3). Lungs from 
the BCG pMV262(icl) -immunized mice had increased antibody level against Icl as shown in 
Figure 4.  
 We determined the toxic effect of propionate produced from the β-oxidation of odd-chain or 
branched-chain fatty acids. Figure 5 shows that propionate was less toxic for bacteria carrying icl 
plasmids in vitro. Although vitamin-B12 increased the growth rate of both strains BCG pMV262(icl) 
multiplied much faster.  
 
   
Discussion 
 
Several vaccines against tuberculosis are currently undergoing clinical trials [17]. Some of them are 
subunit vaccines. Another approach is the use of recombinant BCG expressing antigens from M. 
tuberculosis. A recombinant M. smegmatis was recently shown to induce potent bactericidal 
immunity against M. tuberculosis [18]. 
The Rv0467 (CAE55284.1) gene codes for Icl in M. tuberculosis H37Rv. In M. bovis BCG, 
the icl gene (GenBank accession no. CAL70492) differs in only one base and the amino acid 
composition is identical. The avirulent strain (M. tuberculosis H37Ra) has the same protein 
(GenBank accession no. ABQ72194). Sequence search was done using NCBI. Although we cloned 
icl from H37Rv, because of the identity the extended survival we observed should be due only to 
the increased copy number.  
 The tricarboxylic acid cycle and the glyoxylate shunt together supply bacteria with both 
energy and precursors for carbohydrate synthesis from fatty acids.  Icl has an important role in the 
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methylcitrate cycle too where the processing of the toxic propionate occurs [7]. Thanks to the 
suggestion of an anonymous reviewer we determined the growth rate of the bacteria in the presence 
of propionate in vitro. Bacteria with increased icl copy multiplied much faster wich can contribute 
to the increased number and survival in mice. The „lipid lunch” [19] results in long term survival. 
Being an enzyme expressed in the later stages of infection by M. tuberculosis, Icl may induce long-
term protection if overexpressed from multicopy plasmids during BCG vaccination. In addition, the 
extended survival of this recombinant BCG itself may increase the efficacy of the vaccine. Western 
blot shows increased antibody response. It would be interesting to know the protective effect of this 
recombinant BCG. Because of the lack of biosafety level 3 facilities, we cannot perform these types 
of experiments. 
 The mycobacterial cell wall is very rich in lipids: there are around 250 distinct enzymes 
involved in fatty acid metabolism, five times more than in E. coli [13]. We used ApoB100-only 
LDLR-/-  mice to gain an insight into the role of a high-fat diet on the course of infection, but no 
significant differences were observed with the different diets (unpublished data).  
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Fig. 1 Spleen masses (g) after 10 ( ), 14 ( ), 21 ( ) and 35 ( ) days of infection. 
 
 
Fig. 2 Differences in spleen size. Spleens were removed from mice 21 days after infection with 
BCGpMV262 (lower) or BCGpMV262(icl) (upper).  
 
 
Fig. 3 Colony-forming units in 100 µl of tissue suspension from the spleen and lungs of infected animals 
after 10 ( ), 14 ( ), 21 ( ) and 35 ( ) days of infection. The CFUs were significantly higher in the 
samples from BCGpMV262(icl) than in those from BCGpMV262-infected mice (P<0.005). 
 
 
Fig. 4 BCGpMV262(icl) immunized and control mouse homogenized lungs were tested in Western blot 
assay. Purified control protein (chlamydial LcrH) (lanes 1, 3) and cell lysates from Icl expressing E. coli 
(lanes 2, 4) were probed with BCGpMV262(icl) immunized (lanes 1, 2) and with BCGpMV262 
immunized mouse homogenized lungs in 1:10 dilution (lanes 3, 4). 
 
 
 
 
 
 
Fig. 5 Growth curves in the presence of sodium propionate (0.1%) and with vitamin-B12 addition 
(10µg/ml). Growth was monitored by measuring the optical density of cultures using at least two 
independent experiments.  
